MX9802130A - SELECTIVE 'beta'3 ADRENERGIC AGONISTS. - Google Patents

SELECTIVE 'beta'3 ADRENERGIC AGONISTS.

Info

Publication number
MX9802130A
MX9802130A MX9802130A MX9802130A MX9802130A MX 9802130 A MX9802130 A MX 9802130A MX 9802130 A MX9802130 A MX 9802130A MX 9802130 A MX9802130 A MX 9802130A MX 9802130 A MX9802130 A MX 9802130A
Authority
MX
Mexico
Prior art keywords
beta
selective
diabetes
adrenergic agonists
type
Prior art date
Application number
MX9802130A
Other languages
Spanish (es)
Inventor
Cynthia Darshini Jesudason
Donald Paul Matthews
John Hampton Mcdonald Iii
David Andrew Neel
Christopher John Rito
Anthony John Shuker
Michael Gregory Bell
Thomas Alan Crowell
Christine Ann Droste
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX9802130A publication Critical patent/MX9802130A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective 'beta'3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating Type II diabetes, comprising administering to a mammal in need thereof compounds of Formulas (I) and (II).
MX9802130A 1995-09-21 1996-09-20 SELECTIVE 'beta'3 ADRENERGIC AGONISTS. MX9802130A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US408295P 1995-09-21 1995-09-21
PCT/US1996/015135 WO1997010825A1 (en) 1995-09-21 1996-09-20 SELECTIVE β3 ADRENERGIC AGONISTS

Publications (1)

Publication Number Publication Date
MX9802130A true MX9802130A (en) 1998-05-31

Family

ID=21709052

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9802130A MX9802130A (en) 1995-09-21 1996-09-20 SELECTIVE 'beta'3 ADRENERGIC AGONISTS.

Country Status (19)

Country Link
US (5) US6060492A (en)
EP (1) EP0764640A1 (en)
JP (1) JPH11512701A (en)
KR (1) KR19990045726A (en)
CN (1) CN1202107A (en)
AU (1) AU715175B2 (en)
BR (1) BR9610852A (en)
CA (1) CA2232434A1 (en)
CZ (1) CZ82098A3 (en)
EA (1) EA002778B1 (en)
HU (1) HUP9802814A3 (en)
IL (1) IL119270A0 (en)
MX (1) MX9802130A (en)
NO (1) NO981203L (en)
NZ (1) NZ318718A (en)
PL (1) PL327408A1 (en)
TR (1) TR199800518T1 (en)
WO (1) WO1997010825A1 (en)
ZA (1) ZA967892B (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037967A1 (en) * 1996-04-09 1997-10-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
TW483881B (en) * 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
US7202261B2 (en) * 1996-12-03 2007-04-10 Nps Pharmaceuticals, Inc. Calcilytic compounds
GB9703492D0 (en) * 1997-02-20 1997-04-09 Smithkline Beecham Plc Novel compounds
CO5011072A1 (en) * 1997-12-05 2001-02-28 Lilly Co Eli ETANOLAMINAS PIRAZINIL SUBSTITUTED AS AGFONISTS OF THE RECEPTORS
AU1617499A (en) 1997-12-05 1999-06-28 Eli Lilly And Company Selective beta3 adrenergic agonists
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
US6673827B1 (en) 1999-06-29 2004-01-06 The Uab Research Foundation Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
EP1047692B1 (en) 1998-01-14 2004-07-21 The Uab Research Foundation Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof and methods of treating bacterial and microbial infections with these inhibitors
EP0947494A1 (en) * 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and phenoxymethyltetrazole having antitumor activity
TR200101336T2 (en) * 1998-11-11 2001-11-21 Smithkline Beecham P.L.C. Combinations with a beta-agonist and another antidiabetic agent
EP1142883A4 (en) * 1998-12-15 2002-08-21 Asahi Chemical Ind Novel heterocyclic compounds and drug compositions containing the same
US20020143034A1 (en) * 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
AUPP796798A0 (en) * 1998-12-30 1999-01-28 Fujisawa Pharmaceutical Co., Ltd. New compound
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
AU6049500A (en) * 1999-07-22 2001-02-13 Eli Lilly And Company Treatment of cardiac abnormalities with aryloxy propanolamines
AU6050000A (en) * 1999-07-22 2001-02-13 Eli Lilly And Company Improved method of treating type ii diabetes and obesity
AU1580001A (en) * 1999-11-15 2001-05-30 Eli Lilly And Company Process for the preparation of aryloxy propanolamines
WO2001035947A2 (en) * 1999-11-15 2001-05-25 Eli Lilly And Company Treating wasting syndromes with aryloxy propanolamines
JP2003514815A (en) * 1999-11-15 2003-04-22 イーライ・リリー・アンド・カンパニー Allyloxypropanololamine for improving livestock production
US6841563B1 (en) 1999-11-15 2005-01-11 Eli Lilly And Company Aryloxy propanolamines for improving livestock production
US6534504B1 (en) 1999-11-15 2003-03-18 Eli Lilly And Company Indazolyloxy propanolamines for improving livestock production
AU1572201A (en) * 1999-11-15 2001-05-30 Eli Lilly And Company Crystalline salts of (S)-4-(3-(N-(2-(4-(5-carbamoyl-2-pyridyloxy)phenyl)-1,1- dimethylethyl)amino)-2-hydroxypropoxy)indole
SK632003A3 (en) * 2000-07-13 2003-06-03 Lilly Co Eli Beta3 adrenergic agonists
US6444685B1 (en) 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6395762B1 (en) 2000-07-17 2002-05-28 American Home Products Corporation Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6514991B2 (en) 2000-07-17 2003-02-04 Wyeth Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists
US6451814B1 (en) * 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
US6509358B2 (en) 2000-07-17 2003-01-21 Wyeth Piperidino-phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6458817B1 (en) 2000-07-17 2002-10-01 Wyeth Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists
US6410734B1 (en) 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6498170B2 (en) 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
US6825220B2 (en) 2000-11-10 2004-11-30 Eli Lilly And Company 3-Substituted oxindole β 3 agonists
AR035605A1 (en) 2000-12-11 2004-06-16 Bayer Corp DERIVATIVES OF AMINOMETIL CHROMANO DI-SUBSTITUTES, A METHOD FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF USEFUL MEDICINES AS BETA-3-ADRENE-RECEPTORS AGONISTS
AR035858A1 (en) 2001-04-23 2004-07-21 Bayer Corp CHROME DERIVATIVES 2,6-SUBSTITUTES, PHARMACEUTICAL COMPOSITIONS, USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF USEFUL MEDICINES AS BETA-3 ADRENORRECEPTING AGONISTS
WO2002094820A1 (en) * 2001-05-23 2002-11-28 Eli Lilly And Company Crystalline salts of 2-(4-{2-[2-hydroxy-3-(2-thiophen-2-yl-phenoxy)-propylamino]-2-methyl-propyl}-phenoxy)-nicotinonitrile
ATE340794T1 (en) 2001-08-14 2006-10-15 Lilly Co Eli INDOLE DERIVATIVES AS BETA-3 ADRENERGIC AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES
WO2003016276A2 (en) * 2001-08-14 2003-02-27 Eli Lilly And Company 3-substituted oxindole beta-3 agonists
MXPA04001785A (en) 2001-09-14 2004-07-08 Bayer Ag Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists.
ATE494912T1 (en) * 2001-10-29 2011-01-15 Boehringer Ingelheim Int MNK KINASE HOMOLOGUE PROTEINS INVOLVED IN REGULATION OF ENERGY HOMEOSTASIS AND ORGANAL METABOLISM
US6653323B2 (en) * 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
ES2242890T3 (en) 2001-11-20 2005-11-16 Eli Lilly And Company BETA 3 AGONISTS OF OXINDOL 3-REPLACED.
DE60225174T2 (en) 2001-11-20 2009-02-12 Eli Lilly And Co., Indianapolis BETA-3 ADRENERGIC AGONISTS
EP1467733A1 (en) 2002-01-11 2004-10-20 Eli Lilly And Company 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists
DK1562595T3 (en) * 2002-09-19 2008-08-18 Lilly Co Eli Diarylethers as opioid receptor antagonists
EP1722120A4 (en) * 2004-03-02 2012-10-24 Ntn Toyo Bearing Co Ltd Rotation transmission device
US7317023B2 (en) * 2004-07-21 2008-01-08 Theravance, Inc. Diaryl ether β2 adrenergic receptor agonists
WO2007077111A1 (en) * 2005-12-30 2007-07-12 F. Hoffmann-La Roche Ag Compounds and methods for carbazole synthesis
WO2011075777A1 (en) 2009-12-21 2011-06-30 The University Of Queensland Neuronal stimulation
WO2012058130A1 (en) 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
JO3192B1 (en) 2011-09-06 2018-03-08 Novartis Ag Benzothiazolone compound
ES2394349B1 (en) 2012-08-29 2013-11-04 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Use of selective beta-3 adrenergic receptor agonists for the treatment of pulmonary hypertension
JP2015533081A (en) 2012-10-02 2015-11-19 イーライ リリー アンド カンパニー How to improve chicken products
WO2016210292A1 (en) 2015-06-25 2016-12-29 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
EP3429603B1 (en) 2016-03-15 2021-12-29 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
JP7065951B2 (en) 2017-09-22 2022-05-12 ジュビラント エピパッド エルエルシー Heterocyclic compound as a PAD inhibitor
CA3080677A1 (en) 2017-11-06 2019-05-09 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
MX2020005363A (en) 2017-11-24 2020-10-01 Jubilant Episcribe Llc Heterocyclic compounds as prmt5 inhibitors.
MX2020009517A (en) 2018-03-13 2021-01-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation.
CN114380811A (en) * 2021-12-29 2022-04-22 天和药业股份有限公司 Synthetic method of lubaibailong

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE379196B (en) * 1971-06-24 1975-09-29 Sandoz Ag
DE2815926A1 (en) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh NEW CARBAZOLYL- (4) -OXY-PROPANOLAMINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
ES421880A1 (en) * 1973-12-28 1976-04-01 Elmu Sa Procedure for obtaining pharmacologically active 1-timoxi-2-propanol-amines. (Machine-translation by Google Translate, not legally binding)
JPS5310974B2 (en) * 1974-06-10 1978-04-18
CH624395A5 (en) * 1976-01-08 1981-07-31 Ciba Geigy Ag
DE2609645A1 (en) * 1976-03-09 1977-09-15 Boehringer Sohn Ingelheim AMINOALKYLHETEROCYCLES
DE2645710C2 (en) * 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-aminopropanols, process for their manufacture and pharmaceutical preparation
DE2830211A1 (en) * 1977-07-21 1979-02-01 Sandoz Ag SUBSTITUTED INDOL DERIVATIVES, THEIR PRODUCTION AND USE
US4235919A (en) * 1977-07-21 1980-11-25 Sandoz Ltd. 1-(Indol-4-yloxy)-3-(2-substituted amino)-2-propanols and pharmaceutical use thereof
CA1108619A (en) * 1977-08-12 1981-09-08 Carl H. Ross 4-hydroxy-2-benzimidazolinone derivatives and the preparation thereof
ES465788A1 (en) * 1978-01-05 1979-01-01 Lafarquim Procedure for obtaining a morpholine derivative and its salts. (Machine-translation by Google Translate, not legally binding)
DE2805404A1 (en) * 1978-02-09 1979-08-16 Merck Patent Gmbh 1-ARYLOXY-3-NITRATOALKYLAMINO-2-PROPANOLS AND METHOD FOR THE PRODUCTION THEREOF
DE2965655D1 (en) * 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
US4391826A (en) * 1978-07-03 1983-07-05 Eli Lilly And Company Phenethanolamines, compositions containing the same, and method for effecting weight control
CH636856A5 (en) * 1978-07-17 1983-06-30 Sandoz Ag 4-(3-Aminopropoxy)indole derivatives, their preparation and medicines containing them
US4751246A (en) * 1978-08-30 1988-06-14 Sterling Drug Inc. Compositions and method
DE2905877A1 (en) * 1979-02-16 1980-08-28 Boehringer Mannheim Gmbh NEW AMINOPROPANOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DD150456A5 (en) * 1979-03-01 1981-09-02 Ciba Geigy Ag PROCESS FOR THE PREPARATION OF DERIVATIVES OF 3-AMINO-1,2-PROPANDIOL
EP0021636B1 (en) * 1979-06-16 1982-12-01 Beecham Group Plc Secondary amines, their preparation and use in pharmaceutical compositions
EP0023385B1 (en) * 1979-06-16 1982-12-15 Beecham Group Plc Ethanamine derivatives, their preparation and use in pharmaceutical compositions
EP0025331B1 (en) * 1979-09-06 1983-03-02 Beecham Group Plc Cinnamic acid derivatives, their preparation, and pharmaceutical compositions containing them
EP0040000B1 (en) * 1980-05-08 1983-10-12 Beecham Group Plc Arylethanolamine derivatives, their preparation and use in pharmaceutical compositions
EP0040915B1 (en) * 1980-05-22 1984-03-21 Beecham Group Plc Arylethanolamine derivatives, their preparation and use in pharmaceutical compositions
CA1175851A (en) * 1980-09-26 1984-10-09 Beecham Group Limited Secondary amines
GB2096988B (en) * 1980-11-20 1984-08-01 Beecham Group Ltd Aromatic hydroxyamines
EP0066351B1 (en) * 1981-03-06 1985-06-26 Beecham Group Plc Arylethanol amine derivatives, their preparation and use in pharmaceutical compositions
DE3260490D1 (en) * 1981-03-31 1984-09-06 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
EP0063004A1 (en) * 1981-04-09 1982-10-20 Beecham Group Plc Secondary amines, processes for their preparation, and pharmaceutical compositions containing them
EP0068669A1 (en) * 1981-06-20 1983-01-05 Beecham Group Plc Secondary phenylethanol amines, processes for their preparation and their pharmaceutical application
EP0070134B1 (en) * 1981-07-11 1985-11-13 Beecham Group Plc Secondary phenyl ethanol amines and their pharmaceutical use
IE54220B1 (en) * 1981-12-23 1989-07-19 Ici Plc Phenol esters
EP0089154A3 (en) * 1982-03-12 1984-08-08 Beecham Group Plc Ethanolamine derivatives, their preparation and use in pharmaceutical compositions
FR2523965B1 (en) * 1982-03-24 1985-09-27 Bellon Labor Sa Roger (BENZIMIDAZOLYL-1) -1, N - ((HYDROXY-4 METHOXY-3 PHENYL) -2 HYDROXY-2 ETHYL) 3-AMINO BUTANE AND ITS B-ADRENERGIC SALTS, THEIR THERAPEUTIC APPLICATIONS, AND PROCESS FOR PREPARING THEM
EP0091749A3 (en) * 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
EP0095827B1 (en) * 1982-04-08 1985-07-24 Beecham Group Plc N-substituted derivatives of ethanol amine
CA1219865A (en) * 1982-05-14 1987-03-31 Leo Alig Aziridine phenethanolamine derivatives
EP0099707B1 (en) * 1982-07-16 1986-12-10 Beecham Group Plc 2-aminoethyl ether derivatives, processes for their preparation and pharmaceutical compositions containing them
EP0102213A1 (en) * 1982-08-21 1984-03-07 Beecham Group Plc Ethanolamine derivatives, pharmaceutical compositions containing them, and processes for preparing them
DE3319027A1 (en) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim METHOD FOR PRODUCING OPTICALLY ACTIVE CARBAZOL DERIVATIVES, NEW R- AND S-CARBAZOL DERIVATIVES, AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
CA1262729A (en) * 1983-10-19 1989-11-07 Leo Alig Phenoxypropanolamines
US5166218A (en) * 1983-10-19 1992-11-24 Hoffmann-La Roche Inc. Phenoxypropanolamines and pharmaceutical compositions thereof
GB8419797D0 (en) * 1984-08-03 1984-09-05 Beecham Group Plc Compounds
GB8507942D0 (en) * 1985-03-27 1985-05-01 Beecham Group Plc Compounds
IL79323A (en) * 1985-07-10 1990-03-19 Sanofi Sa Phenylethanolaminotetralines,their preparation and pharmaceutical compositions containing them
GB8519154D0 (en) * 1985-07-30 1985-09-04 Ici Plc Aromatic ethers
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
GB8714901D0 (en) * 1986-07-23 1987-07-29 Ici Plc Amide derivatives
EP0300290B1 (en) * 1987-07-21 1991-12-18 F. Hoffmann-La Roche Ag Phenoxypropanol amines
DE3800096A1 (en) * 1988-01-05 1989-07-13 Bayer Ag USE OF BENZIMIDAZOLE DERIVATIVES AS A POWER SUPPORT
GB8801306D0 (en) * 1988-01-21 1988-02-17 Ici Plc Chemical compounds
US5013761A (en) * 1988-06-03 1991-05-07 Eli Lilly And Company Serotonin antagonists
ZA894145B (en) * 1988-06-03 1991-02-27 Lilly Co Eli Serotonin antagonists
IT1226726B (en) * 1988-07-29 1991-02-05 Zambon Spa ACTIVE COMPOUNDS AS CHOLESTEROL BIOSYNTHESIS INHIBITORS.
US5254595A (en) * 1988-12-23 1993-10-19 Elf Sanofi Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
FR2640969B1 (en) * 1988-12-23 1991-11-22 Midy Spa
GB8905336D0 (en) * 1989-03-08 1989-04-19 Ici Plc Chemical compounds
DE4040186A1 (en) * 1989-12-20 1991-06-27 Hoechst Ag Use of 3-amino-propan-1,2-di:ol derivs. - as racemate, enantiomeric mixt. or pure enantiomer in treatment of diabetes mellitus
IE65511B1 (en) * 1989-12-29 1995-11-01 Sanofi Sa New phenylethanolaminomethyltetralins
US5360811A (en) * 1990-03-13 1994-11-01 Hoechst-Roussel Pharmaceuticals Incorporated 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents
US5061727A (en) * 1990-05-04 1991-10-29 American Cyanamid Company Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
SE467797B (en) * 1991-01-16 1992-09-14 Excelsior Dev Inc TORQUE NUTS OR TIGHTNESS SCREW WITH CONIC THREAD TAPE
EP0499755A1 (en) * 1991-02-18 1992-08-26 MIDY S.p.A. Phenylethanolaminotetralines, process for their preparation, intermediates of this process and pharmaceutical compositions containing them
GB9107827D0 (en) * 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
GB9207964D0 (en) * 1992-04-10 1992-05-27 Ici Plc Chemical compounds
GB9209076D0 (en) * 1992-04-27 1992-06-10 Ici Plc Chemical compounds
GB9215844D0 (en) * 1992-07-25 1992-09-09 Smithkline Beecham Plc Novel compounds
WO1994003425A2 (en) * 1992-07-31 1994-02-17 Syntex (U.S.A.) Inc. Carbostyril derivatives for the treatment of arrhythmia
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
US5321036A (en) * 1993-02-10 1994-06-14 Bristol-Myers Squibb Company Thiazole and oxazole-based β3 adrenergic receptor agonists
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
EP0627407A1 (en) * 1993-05-28 1994-12-07 MIDY S.p.A. (7S)-7-(2(3-chlorophenyl)-2-hydroethylamino-5,6,7,8-tetrahydro-naphthalen-2-yloxy acetic acid, their pharmaceutically acceptable salts with a beta-3-adrenergic agonist activity and pharmaceutical compositions containing them
US5767133A (en) * 1993-06-14 1998-06-16 Pfizer Inc. Secondary amines as antidiabetic and antiobesity agents
GB9313574D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Medicaments
WO1995004047A1 (en) * 1993-07-31 1995-02-09 Smithkline Beecham Plc 2-benzoheterocyclyloxy or thiopropanolamine derivatives with adreno receptor agonist activity
IL110857A0 (en) * 1993-09-09 1994-11-28 Lilly Co Eli Cessation of tobacco use
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5561142A (en) * 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5541197A (en) * 1994-04-26 1996-07-30 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug response by a serotonin 1A receptor antagonist
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US6075040A (en) * 1996-09-05 2000-06-13 Eli Lilly And Company Selective β3 adrenergic agonists

Also Published As

Publication number Publication date
CZ82098A3 (en) 1998-08-12
KR19990045726A (en) 1999-06-25
US5977154A (en) 1999-11-02
US6093735A (en) 2000-07-25
AU715175B2 (en) 2000-01-20
CN1202107A (en) 1998-12-16
EP0764640A1 (en) 1997-03-26
US6060492A (en) 2000-05-09
TR199800518T1 (en) 1998-06-22
HUP9802814A2 (en) 1999-10-28
US5939443A (en) 1999-08-17
BR9610852A (en) 1999-07-13
CA2232434A1 (en) 1997-03-27
NO981203L (en) 1998-05-06
PL327408A1 (en) 1998-12-07
JPH11512701A (en) 1999-11-02
HUP9802814A3 (en) 2002-12-28
WO1997010825A1 (en) 1997-03-27
EA199800316A1 (en) 1998-10-29
ZA967892B (en) 1998-03-18
US5786356A (en) 1998-07-28
NO981203D0 (en) 1998-03-17
IL119270A0 (en) 1996-12-05
NZ318718A (en) 1999-10-28
EA002778B1 (en) 2002-08-29
AU7077896A (en) 1997-04-09

Similar Documents

Publication Publication Date Title
MX9802130A (en) SELECTIVE 'beta'3 ADRENERGIC AGONISTS.
MY132626A (en) CARBAZOLYL-SUBSTITUTED ETHANOLAMINES AS SELECTIVE ß-3 AGONISTS
HUT74452A (en) Preparation for substitution therapy, containing at least one progestogen and at least one extrogen
ATE207352T1 (en) NON-ALLOSTERIC GABA A AGONISTS FOR THE TREATMENT OF SLEEP DISORDERS
HUP9700368A2 (en) Treating of type ii diabetes mellitus with amylin agonists
PT784476E (en) TREATMENT OF MULTIPLE SCLEROSIS (EM) AND OTHER DEMELINIZING CONDITIONS USING LOFEPRAMINE IN COMBINATION WITH L-PHENYLALANINE TYROSINE OR TRIPTOFAN AND OPTIONALLY A COMPOUND OF VITAMIN B 12
NO972128D0 (en) 2,2-dichloroalkanecarboxylic acids, process for their preparation, drug containing them and their use for the treatment of insulin resistance
AU7077096A (en) Selective beta 3 adrenergic agonists
TW261532B (en)
SG49239A1 (en) Amylin and possibly insulin containing composition for the treatment of aneroxia and related states
HK1010152A1 (en) Novel medical use
CA2236269A1 (en) Selective .beta.3 adrenergic agonists
ATE200624T1 (en) USE OF 4'-IODO - 4 - DEOXYDOXORUBICIN FOR THE TREATMENT OF AMYLOIDOSIS
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
MX9708618A (en) 'beta'-ADRENERGIC AGONISTS.
UA8278A (en) Method for treating psoriasis
UA9522A (en) Method for treating autoimmune thyroiditis
PL322847A1 (en) Condensed b-carbolins
RU94023697A (en) Method for treating early age children possessing infectious toxicosis
UA31672A (en) Method for treating sepsis
UA10210A (en) Method for treatment of urogenital clamidiosis